The Business of healthcare innovation /
The Business of healthcare innovation /
edited by Lawton Robert Burns
- Third Edition
- Cambridge, United Kingdom : Cambridge University Press, c2020
- 492 pages : illustrations ; 25 cm.
Includes bibliographical references and index.
1. Product suppliers in the health care value chain Lawton Robert Burns -- 2. The pharmaceutical sector Richard T. Evans and Scott Hinds -- 3. The biotechnology sector - therapeutics Cary G. Pfeffer -- 4. New venture creation in biotechnology Jason Rhodes and Lawton Robert Burns -- 5. The medical device sector Kurt H. Kruger and Max A. Kruger -- 6. Financing medtech innovation Justin Klein -- 7. The healthcare information technology sector Adam C. Powell and John Glaser.
Perhaps as never before, countries around the world are looking at biomedical innovation as a source of (a) knowledge creation by their scientific communities, (b) value creation for their populations, and (c) wealth creation by fostering industries and expansion of employment. In the U.S., for example, bipartisan passage of the 21st Century Cures Act of 2016 seeks to accelerate new product development and faster patient access to new treatments and therapies. It also elevates the role of biomedical research through an additional
9781108749060
BUSINESS FORECASTING
R 855.3 .B87 2020
Includes bibliographical references and index.
1. Product suppliers in the health care value chain Lawton Robert Burns -- 2. The pharmaceutical sector Richard T. Evans and Scott Hinds -- 3. The biotechnology sector - therapeutics Cary G. Pfeffer -- 4. New venture creation in biotechnology Jason Rhodes and Lawton Robert Burns -- 5. The medical device sector Kurt H. Kruger and Max A. Kruger -- 6. Financing medtech innovation Justin Klein -- 7. The healthcare information technology sector Adam C. Powell and John Glaser.
Perhaps as never before, countries around the world are looking at biomedical innovation as a source of (a) knowledge creation by their scientific communities, (b) value creation for their populations, and (c) wealth creation by fostering industries and expansion of employment. In the U.S., for example, bipartisan passage of the 21st Century Cures Act of 2016 seeks to accelerate new product development and faster patient access to new treatments and therapies. It also elevates the role of biomedical research through an additional
9781108749060
BUSINESS FORECASTING
R 855.3 .B87 2020